


FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
1040-5SERIAL-NO.
09/650,055INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Kay et al.FILING DATE
August 29, 2000GROUP
Unassigned

(Use several sheets if necessary)

RECEIVED
JAN 19 2001RECEIVED
JAN 19 2001

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	3,683,076	Aug. 8, 1972	Rovati	424	180	
	3,911,098	Oct. 7, 1975	Capozza	424	22	
	4,006,224	Feb. 1, 1977	Prudden	424	180	
	4,228,161	Oct. 14, 1980	Shen	424	232	
	4,647,453	Mar. 3, 1987	Meisner	424	54	
	4,704,268	Nov. 3, 1987	Kifune	424	488	
	4,772,591	Sep. 20, 1988	Meisner	514	62	
	5,364,845	Nov. 15, 1994	Henderson	514	54	
	5,582,837	Dec. 10, 1996	Shell	424	481	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		1.	Baron et al., "Glucosamine Induces Insulin Resistance In Vivo By Affecting GLUT 4 Translocation in Skeletal Muscle," <i>J. Clin. Investigation, Inc.</i> , 96:2792-2801, (December 1995).

EXAMINER

DATE CONSIDERED

September 16, 2002

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
1040-5

SERIAL NO.
09/650,055


INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT
Kay et al.

FILING DATE
August 29, 2000

GROUP
Unassigned

(Use several sheets if necessary)



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
<i>[Handwritten Initials]</i>	5,587,363	Dec. 24, 1996	Henderson	5M	54	
<i>[Handwritten Initials]</i>	5,681,585	Oct. 28, 1997	Oshlack et al.	424	494	
<i>[Handwritten Initials]</i>	5,716,631	Feb. 10, 1998	Drizen et al.	424	422	
<i>[Handwritten Initials]</i>	5,736,152	Apr. 7, 1998	Dunn	424	426	
<i>[Handwritten Initials]</i>	5,840,715	Nov. 24, 1998	Florio	514	62	
<i>[Handwritten Initials]</i>	5,843,919	Dec. 1, 1998	Burger	514	62	
<i>[Handwritten Initials]</i>	5,846,952	Dec. 8, 1998	Vournakis et al.	514	55	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>[Handwritten Initials]</i>		2.	McClain et al., "Hexosamines and Insulin Resistance," <i>Diabetes</i> , # 45:1003-1009, (1996).
-------------------------------	--	----	---

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
1040-5SERIAL NO.
09/650,055INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Kay et al.FILING DATE
August 29, 2000GROUP
Unassigned

(Use several sheets if necessary)



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
<i>[Signature]</i>	5,849,336	Dec. 15, 1998	Aoyagi et al.	424	570	
<i>[Signature]</i>	5,855,915	Jan. 5, 1999	Pinkus	424	400	
<i>[Signature]</i>	5,888,514	Mar. 30, 1999	Weisman	424	195.1	
<i>[Signature]</i>	5,916,565	June 29, 1999	Rose et al.	424	195.1	
<i>[Signature]</i>	5,994,324	Nov. 30, 1999	Ashida et al.	514	570	
<i>[Signature]</i>	6,007,843	Dec. 28, 1999	Drizen et al.	424	480	
<i>[Signature]</i>	6,020,002	Feb. 1, 2000	Myers et al.	424	480	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		3. Talent et al., "Pilot Study of Oral Polymeric N-acetyl-D-glucosamine as a Potential Treatment for Patients with Osteoarthritis (Abstract)," <i>Clin. Ther.</i> , 18(6):1184-90, (Nov.-Dec. 1996).
--	--	--

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
1040-5SERIAL NO.
09/650,055INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT
Kay et al.FILING DATE
August 29, 2000GROUP
Unassigned *1114*

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
<i>WJ</i>	6,046,179	Apr. 4, 2000	Murch et al.	<i>514</i>	<i>17</i>	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>WJ</i>		4.	Rege et al., "Chitosans as Tableting Excipients for Modified Release Delivery Systems (ABSTRACT)," <i>Int. J. Pharm</i> , 181 (1):49-60, (April 20, 1999).
-----------	--	----	--

EXAMINER *WJ*DATE CONSIDERED *September 16, 2001*

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.